Canadian study finds minimal evidence of weaker COVID-19 vaccine responses in people with HIV

Moderna vaccine as a third dose produced especially strong responses

People with undetectable HIV who received SARS-CoV-2 vaccines didn’t experience faster antibody declines than people without HIV after two vaccine doses and had equivalent or better antibody responses compared to a control group after a third dose, especially those who received the Moderna vaccine as their third dose, Canadian researchers report in a pre-print article released before peer review.

The study found no evidence of weaker virus neutralisation nor any evidence of weaker vaccine responses in people with a history of a low CD4 cell count. Most people in this study received the Pfizer or Moderna mRNA vaccines but there was some evidence that the Oxford-AstraZeneca vaccine was associated with weaker responses after the first two doses.

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below